Pulse Biosciences Schedules Second Quarter 2021 Financial Results Conference Call for August 9, 2021

Rhea-AI Summary

Pulse Biosciences (Nasdaq: PLSE) will release its financial results for Q2 2021 after market close on August 9, 2021. A conference call led by management will follow at 1:30 PM PT. The company focuses on Nano-Pulse Stimulation™ (NPS™) technology, with its CellFX® System being the first commercial product designed for dermatologic applications, allowing for the non-thermal treatment of cells while preserving surrounding tissue. This multi-application platform adopts a utilization-based revenue model, intending to elevate patient outcomes.

Positive

• The CellFX System utilizes Nano-Pulse Stimulation technology, offering innovative treatments for dermatologic conditions.
• The company's proprietary technology allows for effective non-thermal cell treatment, improving patient outcomes.

Negative

• None.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2021 after market close on Monday, August 9, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.

Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.

To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005764/en/

FAQ

When will Pulse Biosciences report its Q2 2021 financial results?

Pulse Biosciences will report its financial results for Q2 2021 on August 9, 2021, after market close.

What is the conference call schedule for Pulse Biosciences' Q2 2021 earnings?

The conference call for Pulse Biosciences' Q2 2021 earnings is scheduled for 1:30 PM PT on August 9, 2021.

What technology does Pulse Biosciences' CellFX System use?

The CellFX System uses Nano-Pulse Stimulation™ (NPS™) technology for non-thermal cell treatment.

What are the applications of the CellFX System?

The CellFX System is designed for treating various dermatologic conditions, addressing high demand for improved outcomes.

How does Pulse Biosciences generate revenue?

Pulse Biosciences employs a utilization-based revenue model for its CellFX System, promoting customer value.